BIND Therapeutics
BIND Therapeutics: A new way of targeting disease
Product Development Pipeline
We intend to use our medicinal nanoengineering platform to develop Accurins in several therapeutic areas, with an initial focus on the treatment of various types of cancer. In addition, we have entered into collaboration agreements with several major biopharmaceutical companies to develop and commercialize Accurins that are based on our collaborators' proprietary therapeutic payloads and targeting ligands. The following table depicts our proprietary and collaboration products in development:

Proprietary Programs
BIND-014
(PSMA-targeted docetaxel)
KRAS-mutated non-small cell lung cancer (NSCLC)

Squamous histology NSCLC


 
BIND-510
(PSMA-targeted vincristine)
Solid tumor Accurin

Hematologic cancer Accurin


 
PLK1-, KSP-inhibitor Accurins
Multiple PLK1 oncology targets

Multiple KSP oncology targets




Ongoing Collaboration Programs

AstraZeneca BIND
AZD2811
(Aurora B kinase inhibitor)
 
Pfizer BIND
Targeted
therapies

 
Merck BIND
Multiple oncology
targets
 
 
Macrophage BIND
 
CD206 targeting

PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
 


 

 

 
 
 

















Partnered Programs
In addition to our internal development programs, we actively seek opportunities to collaborate with recognized biopharmaceutical companies to develop Accurins incorporating therapeutic payloads and targeting ligands from their proprietary product portfolios. We have established a number of collaborations with industry leaders, including announced agreements with Pfizer, AstraZeneca, Roche, Merck, Macrophage Therapeutics (a subsidary of Navidea Biopharmaceuticals, Inc.) and Amgen. Please see Partnerships section for more information.